Welcome to 'tissue therapeutics’: Dave Lennon’s $110M new venture will implant ‘happy cells’ that ‘survive and thrive’
You’ve heard of cell therapies. You’ve certainly heard of gene therapies. But have you heard of tissue therapeutics?
Just in time for May flowers, a biotech two decades in the works — longer if you count the co-founders’ first academic encounters as grad student peers in the mid-1990s — has sprung from the shadows of Cambridge, MA to introduce the world to what it deems an “exciting new pillar within the regenerative medicine field.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.